ValiRx - VAL401 Update
VAL Thu, 14 Jun 2018, 11:45 BST
The VAL401 clinical trial and data collection is now complete and the regulatory process is moving towards completion. Dr Suzy Dilly updates us on VAL 401's current and future developments which now focus on the commercial aspects of the completed science development.
Suzanne Dilly
CEO, ValiSeek Limited
Dr Cathy Tralau-Stewart, Chief Scientific Officer
Thu, 21 Mar 2024, 7:05am GMT
Dr Cathy Tralau-Stewart, Chief Scientific Officer
Mon, 12 Feb 2024, 3:00pm GMT
Dr Suzanne Dilly, Chief Executive Officer
Tue, 5 Dec 2023, 2:00pm GMT
Dr Suzanne Dilly, Chief Executive Officer
Thu, 28 Sep 2023, 7:00am BST
Dr Suzanne Dilly, Chief Executive Officer
Wed, 14 Jun 2023, 3:00pm BST
Dr Suzanne Dilly, Chief Executive Officer
Tue, 31 Jan 2023, 2:28pm GMT
Dr Suzanne Dilly, Chief Executive Officer
Thu, 26 Jan 2023, 1:32pm GMT
Professor Martin Ulmschneider, Head of Department of Chemistry - Kings...
Fri, 28 Oct 2022, 4:45pm BST
Dr Suzanne Dilly, Chief Executive Officer
Thu, 29 Sep 2022, 4:27pm BST
Dr Suzanne Dilly, Chief Executive Officer
Thu, 14 Jul 2022, 1:30pm BST
Dr Suzanne Dilly, Chief Executive Officer
Thu, 30 Jun 2022, 11:00am BST
ValiRx - Board Members, ValiRx PLC
Wed, 6 Apr 2022, 5:00pm BST
Dr Suzanne Dilly, Chief Executive Officer
Wed, 23 Mar 2022, 12:56pm GMT
Dr Suzanne Dilly, Chief Executive Officer
Wed, 5 Jan 2022, 12:00pm GMT
Dr Suzanne Dilly, Chief Executive Officer
Mon, 20 Dec 2021, 12:20pm GMT
Dr Suzanne Dilly, Chief Executive Officer
Fri, 26 Nov 2021, 4:48pm GMT
Dr Suzanne Dilly, Chief Executive Officer
Tue, 2 Nov 2021, 5:00pm GMT
Dr Suzanne Dilly, Chief Executive Officer
Fri, 28 May 2021, 12:30pm BST
